Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew P Cope

Showing results (91-100 of 133) with videos related to

Pageof 14
Sort By:
Plos One|October 18, 2017
Protein tyrosine phosphatase PTPN22 is dispensable for dendritic cell antigen processing and promotion of T-cell activation by dendritic cellsFiona Clarke, Christine K Jordan, Enrique Gutiérrez-Martinez, et al.
Scientific Reports|June 24, 2017
3D Bayesian cluster analysis of super-resolution data reveals LAT recruitment to the T cell synapseJuliette Griffié, Leigh Shlomovich, David J Williamson, et al.
Rheumatology (Oxford, England)|November 1, 2024
Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort studyMark D Russell, Zijing Yang, Niamh Dooley, et al.
The Lancet. Rheumatology|October 18, 2024
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort studyMark D Russell, Mark Gibson, Benjamin Zuckerman, et al.
The Lancet. Rheumatology|February 8, 2025
Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis - Authors' replyMark D Russell, Mark Gibson, Benjamin Zuckerman, et al.
Annals of the Rheumatic Diseases|May 29, 2023
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indicationsMark D Russell, Christopher Stovin, Edward Alveyn, et al.
Annals of the Rheumatic Diseases|July 9, 2026
A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trialPaul Emery, Michael E Weinblatt, Vivian P Bykerk, et al.
Annals of the Rheumatic Diseases|January 28, 2025
Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful diseaseKevin D Deane, V Michael Holers, Paul Emery, et al.
Annals of the Rheumatic Diseases|September 6, 2024
Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful diseaseKevin D Deane, V Michael Holers, Paul Emery, et al.
The Lancet. Respiratory Medicine|November 17, 2023
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trialFrances C Hall, Joseph Cheriyan, Andrew P Cope, et al.
Pageof 14

Showing results (91-100 of 133) with videos related to

Sort By:
Pageof 14
Plos One|October 18, 2017
Protein tyrosine phosphatase PTPN22 is dispensable for dendritic cell antigen processing and promotion of T-cell activation by dendritic cellsFiona Clarke, Christine K Jordan, Enrique Gutiérrez-Martinez, et al.
Scientific Reports|June 24, 2017
3D Bayesian cluster analysis of super-resolution data reveals LAT recruitment to the T cell synapseJuliette Griffié, Leigh Shlomovich, David J Williamson, et al.
Rheumatology (Oxford, England)|November 1, 2024
Temporal and regional variation in the use of biologic and targeted synthetic DMARDs for rheumatoid arthritis: a nationwide cohort studyMark D Russell, Zijing Yang, Niamh Dooley, et al.
The Lancet. Rheumatology|October 18, 2024
Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort studyMark D Russell, Mark Gibson, Benjamin Zuckerman, et al.
The Lancet. Rheumatology|February 8, 2025
Refining strategies for biological and targeted synthetic DMARD initiation in rheumatoid arthritis - Authors' replyMark D Russell, Mark Gibson, Benjamin Zuckerman, et al.
Annals of the Rheumatic Diseases|May 29, 2023
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indicationsMark D Russell, Christopher Stovin, Edward Alveyn, et al.
Annals of the Rheumatic Diseases|July 9, 2026
A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trialPaul Emery, Michael E Weinblatt, Vivian P Bykerk, et al.
Annals of the Rheumatic Diseases|January 28, 2025
Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful diseaseKevin D Deane, V Michael Holers, Paul Emery, et al.
Annals of the Rheumatic Diseases|September 6, 2024
Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful diseaseKevin D Deane, V Michael Holers, Paul Emery, et al.
The Lancet. Respiratory Medicine|November 17, 2023
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trialFrances C Hall, Joseph Cheriyan, Andrew P Cope, et al.
Pageof 14